Tuesday, September 15, 2026

Seoul Semiconductor Wins Patent Battle: What This Means for the $50 Billion Photonics Market

SETi wins a patent lawsuit against Laser Components, emphasizing the need for better protection of optical semiconductor technology.

CKDB-501A vs. Botox: Can CKD BiO’s New Botulinum Toxin Compete in China’s Booming Market?

Jongkundang Bio has successfully completed Phase 3 trials in China's botulinum toxin market, signaling global expansion.

ALL Talk, NO Meeting: North Korea Launching Missiles Means Trump Has Officially Given Up And Is Just Waiting For ‘Someday’

Trump hints at future talks with North Korea's Kim, focusing on trade with China but open to engagement at APEC summit.

Tag: Japan

North KoreaKoreaKimMilitaryAISouth Koreamarketrelationsdevelopment

JLK Partners with Takeyama: What This Means for AI Stroke Solutions in Japan’s Medical Market

JLK, a medical AI company, partners with Takeyama to expand its distribution network in Japan, enhancing local presence.

“Why Can’t Stem Cell Treatments Be Offered in Korea?”…Government Maps Out a “Korean Model of Regenerative Medicine”

The debate over stem cell therapy highlights why it's available in Japan but not in South Korea.

HLB Panagene Signs Exclusive PNA Distribution Agreement in Singapore With Roche Affiliate

HLB Panajin signs exclusive distribution deal for PNA with Roche Group's subsidiary, advancing its drug development efforts.

Patients Travel Overseas for Cell Therapies—South Korea Moves to Lower Barriers to Treatment

South Korean patients seek stem cell therapies abroad due to limited options at home, despite high costs and uncertain efficacy.

Huons Meditech Enters Japan’s Aesthetic Market With Exclusive Distribution Agreement for Dermashine Duo_RF

Huons Meditech enters Japan's aesthetic market with its Dermashine Duo_RF device, partnering with Nifuji for distribution and sales.

CARTISTEM vs. Traditional Treatments: What Makes Medipost’s Stem Cell Therapy a Game-Changer?

Medipost to commercialize CARTISTEM in Japan using domestically produced media, enhancing supply chain stability and competitiveness.

U.S., Japan and China Advance Stem Cell Commercialization While Korea Works to Close Gaps

The global stem cell therapy market is rapidly growing, but South Korea faces challenges in commercialization compared to the U.S. and Japan.

Medipost Reports Positive Phase 3 Results for CARTISTEM in Japan’s Knee Osteoarthritis Trial

Medipost's CARTISTEM therapy shows significant efficacy in Phase 3 trials for knee osteoarthritis in Japan, enhancing global competitiveness.

Celltrion Launches New Autoimmune Drug Avtozma in Japan

Celltrion launches Avtozma for autoimmune diseases in Japan, expanding its product portfolio and strengthening market presence.

Celltrion’s Steqeyma IV Approval: What This Means for Celltrion’s Growth in Japan’s Autoimmune Drug Market

Celltrion's Steqeyma IV formulation gains approval in Japan, expanding treatment for Crohn's disease and enhancing market competitiveness.

Neurophet Unveils AI-Powered Alzheimer’s Treatment Software at ITEM 2026 in Japan

Neurophet showcases AI-driven brain disease tech at ITEM 2026 in Japan, partnering with Hokuyaku Takeyama to expand market reach.

Celltrion’s Breakthrough: Why Vegzelma and Herzuma Lead in Japan’s Oncology Market

Celltrion's cancer treatments dominate the Japanese market, with Vegzelma and Herzuma capturing significant shares, showcasing strong growth.

How Celltrion’s Herceptin Biosimilar Herzuma Achieved 74% Market Share in Japan: A Game Changer for Cancer Treatment

Celltrion's Herzuma biosimilar captures 74% of Japan's trastuzumab market, enhancing patient access and leveraging favorable policies.

Medipost’s CARTISTEM® Completes Phase 3 Trials in Japan: What This Means for Knee Osteoarthritis Treatment

Medipost completes Phase 3 trial for CARTISTEM in Japan, targeting knee osteoarthritis treatment and planning U.S. trial enrollment soon.

Top News

- Our Sponsors Ad -

Follow us

Cars

Tech

future

health

© Copyright by News1. All Rights Reserved.